CGEM Cullinan Oncology Inc

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM) (“Cullinan”) announced today that the company’s Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20th Annual Needham Virtual Healthcare Conference.

Event: Needham Virtual Healthcare Conference

Date: Tuesday, April 13th

Time: 11:45am EDT

Location: Virtual

The presentation will be accessible through the Needham conference portal for registered attendees only. Investors interested in scheduling a meeting with Mr. Trigilio should contact their Needham & Company representative.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company that seeks to drive shareholder returns by focusing on the patient. The Company’s strategy is to build a diversified pipeline of targeted and immuno-oncology therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. Learn more about Cullinan at .

Contacts:

Investor Relations

Jeff Trigilio

+1 617.410.4650



EN
07/04/2021

Underlying

CGEMCullinan Oncology Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cullinan Oncology Inc

 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Provides Corporate Update and Reports Second Qua...

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO 2025 and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC 2025 WCLC and ESMO Congress 2025 Company appoints Mittie Doyle, M.D.,...

August 7, 2025 1 EN
Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
CGEM CULLINAN ONCOLOGY INC
08/07/25 August 7, 2025 1 EN
Wedbush Research
  • Wedbush Research
VRNT VERINT SYSTEMS INC.
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
GME GAMESTOP CORP. CLASS A
MDB MONGODB INC. CLASS A
PHVS PHARVARIS NV
CGEM CULLINAN ONCOLOGY INC
PL PLANET LABS PBC
TLX TELIX PHARMACEUTICALS LIMITED
06/05/25 June 5, 2025 1 EN
Ritika Das ... (+2)
  • Ritika Das
  • Robert Driscoll
CGEM CULLINAN ONCOLOGY INC
06/05/25 June 5, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage...

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases Advances Cullinan’s leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028 Company to host conference call today at 4:30 pm ET CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CGEM; “Cullinan”...

June 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch